While biotech bets swing on trial data, this dividend payer gained 72% since 2024 RSS CTA

Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Biotechnology investing often demands a high tolerance for binary risk: a single clinical trial readout or shifting political debate can reprice a pipeline overnight. While names like Moderna (NASDAQ:MRNA) and Biogen (NASDAQ:BIIB) remain heavily tethered to regulatory milestones and trial catalysts, Amgen (NASDAQ:AMGN) operates on an entirely different financial foundation: generating steady, non-cyclical cash flow from commercialized therapies in oncology, bone health, and cardiovascular disease.

That balance-sheet durability is why InvestingPro’s ProPicks AI models added Amgen to the Dominate the Dow strategy back in December 2024—a position that has delivered a 71.8% gain since it was first picked.

With the live November rebalance now in place, the strategy surrounds Amgen with a focused basket of proven cash generators—including a heavy equipment and backup power manufacturer, a global pharmaceutical developer, and a high-yielding national telecom provider.

Revenue From Approved Drugs, with a Pipeline on Top

Amgen reported third-quarter results on November 3, and the commercial side kept growing. Adjusted earnings of $6.45 per share beat estimates by 12.0%, and revenue of $10.4 billion beat by 3.4%, up about 9% from $9.56 billion a year earlier. Amgen has also beaten EPS estimates in each of the eight quarters before this one.

Six key drivers, including cardiovascular drug Repatha, grew 26% and made up about 70% of product sales in the second quarter.

Oncology gives the revenue base more constancy: lung cancer therapy IMDELLTRA grew 115% to $288 million in the second quarter, and its Phase 3 trial in first-line maintenance treatment showed a 58% reduction in the risk of death for IMDELLTRA plus IMFINZI versus IMFINZI alone. The business generated $3.5 billion in free cash flow in the second quarter.

The pipeline gives upside on top of an approved-drug base. MariTide, Amgen’s monthly-dosed obesity candidate, is in nine ongoing Phase 3 studies, and dazodalibep met its primary endpoint in a Phase 3 Sjögren’s disease trial in late October, in a condition with no currently FDA-approved medicines.

Weighing the Run Against the Price

The stock has returned 59.8% over the past year, against 17.0% for its peer group and a 16.7% decline for the sector, and it trades at 97.0% of its 52-week high. Consensus analyst projections compiled on InvestingPro put the forward P/E at 19.9x on 2026 earnings (18.8x on 2027), against 28.5x on trailing earnings. A forward multiple of about 20 and a long beat record help explain the run.

Valuation data is more mixed. InvestingPro’s Fair Value, which aggregates 15 models, averages $456.70 with low uncertainty, 3.7% below the current price. The average analyst target is $404.32 across 29 analysts, and 90-day revisions to next-quarter EPS estimates are split 9 up and 14 down, though TD Cowen and Cantor Fitzgerald lifted their targets to $531 and $465 on November 4. 

Dividends add to the return. Amgen has raised its dividend for 16 consecutive years and yields 2.2%, with $12.5 billion of operating cash flow in the twelve months to June behind it. InvestingPro’s Financial Health framework, which ranks companies on more than 100 factors, rates Amgen Great, with Profitability Health at 4 out of 5, though Relative Value scores 2. Its beta of 0.42 shows how much calmer the shares have been than the market.

Risks include steep biosimilar erosion at Prolia and XGEVA, pricing pressure on Enbrel, a heavy debt load from the Horizon acquisition and an FDA warning letter over Vectibix promotion.

The Amgen Pro Research Report lays out the oncology revenue base, the MariTide and late-stage pipeline catalysts, and the dividend record in full.

Looking Beyond Binary Biotech Bets

Amgen demonstrates the advantage of prioritizing commercial execution over clinical speculation. By pairing a 16-year dividend growth streak and $3.5 billion in quarterly free cash flow with late-stage metabolic pipeline catalysts like MariTide, the company delivers resilient shareholder returns without taking on unhedged clinical volatility.

That discipline defines ProPicks AI’s approach to the market. Rather than chasing headline-driven drug trials, the Dominate the Dow strategy re-evaluates fundamentals monthly, reallocating capital toward blue-chip operators with durable balance sheets and dependable earnings power across industrial infrastructure, pharmaceutical development, and telecom services.

For investors seeking high-conviction ideas in the newly updated portfolios, full access to all ProPicks AI strategies costs just $9 a month.

The author holds no position in the stocks mentioned. Data and financial metrics as of November 4, 2026.